SFC
NBIX icon

SYM Financial Corp’s Neurocrine Biosciences NBIX Stock Holding History

SYM Financial Corp’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$256K Sell
1,942
-97
-5% -$12.9K 0.03% 252
2025
Q4 		$289K Buy
2,039
+281
+16% +$40.7K 0.03% 234
2025
Q3 		$247K Buy
+1,758
New +$238K 0.03% 259

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SYM Financial Corp's NBIX Position: Q1 2026 in Review

SYM Financial Corp reduced its Neurocrine Biosciences (NBIX) stake by 4.8% in Q1 2026, selling an estimated $12.9K and leaving 1,942 shares worth $256K. The position accounts for 0.03% of the portfolio, ranked #252.

SYM Financial Corp first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $289K in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • SYM Financial Corp held 1,942 shares of Neurocrine Biosciences worth $256K as of Q1 2026.
  • SYM Financial Corp sold 97 Neurocrine Biosciences shares in Q1 2026, an estimated $12.9K.
  • Neurocrine Biosciences made up 0.03% of SYM Financial Corp's portfolio in Q1 2026, its #252 holding.
  • SYM Financial Corp first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • SYM Financial Corp's Neurocrine Biosciences position peaked at $289K in Q4 2025.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on SYM Financial Corp's 13F filing for Q1 2026, filed 8 May 2026.